Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — Q1 2022 Earnings Presentation
7 slides from Revvity's earnings presentation, May 3, 2022
Slide 1: 1Q22 Earnings Presentation
1Q22 Earnings Presentation May 3, 2022
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 1Q '22 Financial Results
1Q ‘22 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights Decline -11% Margin 890bps Growth -35% DAS Adjusted Revenue: $1.26 billion; -4% y/y 48% +LDD • Organic: -11%; M&A: +10%; FX: -2% DX 52% • COVID: $310 million vs. $550 million in 1Q21 -DD • Non-COVID: +11% or
Slide 4: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS ✓ +DD organic with Pharma up +DD 1Q22 Performance Food* Life ✓ Discovery +DD driven by strength in Sciences reagents & imaging/detection • +33% reported growth ✓ Informatics strong +DD • Organic: +12%; M&A: +23%; FX: -2% • Backlogs remain strong ✓ +DD organic growth
Slide 5: Diagnostics
DIAGNOSTICS 1Q22 Performance ✓ +MSD organic growth driven by newborn Applied Reproductive screening franchise Genomics Health • -23% reported decline ✓ Menu expansion, improving birth rates in ImmunoDx U.S. & portions of EU • Organic: -24%; M&A: +3%; FX: -2% • Non-COVID diagnostics +10% ✓ -DD organi
Slide 6: Updated Financial Guidance
UPDATED FINANCIAL GUIDANCE 2Q22 Guidance-a) 2022 Guidance-a) • Adjusted Revenue: $1.20-1.22 billion; -2% to -1% reported • Adjusted Revenue: $4.56-4.63 billion; -10% to -9% reported • Organic: -10% to -8%; M&A +10%; FX -3% • Organic: -15% to -14%; M&A +7%; FX -2% Assumptions COVID vs. Non-COVID Outl
Slide 7: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Vice President, Investor Relations | steve.willoughby@perkinelmer.com | @PerkinElmerIR 7